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Abstract: The pathogenesis of hypertension, as a multifactorial trait, is complex. High blood pressure
levels, in turn, concur with the development of cardiovascular damage. Abnormalities of several
neurohormonal mechanisms controlling blood pressure homeostasis and cardiovascular remodeling
can contribute to these pathological conditions. The natriuretic peptide (NP) family (including ANP
(atrial natriuretic peptide), BNP (brain natriuretic peptide), and CNP (C-type natriuretic peptide)),
the NP receptors (NPRA, NPRB, and NPRC), and the related protease convertases (furin, corin,
and PCSK6) constitute the NP system and represent relevant protective mechanisms toward the
development of hypertension and associated conditions, such as atherosclerosis, stroke, myocardial
infarction, heart failure, and renal injury. Initially, several experimental studies performed in different
animal models demonstrated a key role of the NP system in the development of hypertension.
Importantly, these studies provided relevant insights for a better comprehension of the pathogenesis
of hypertension and related cardiovascular phenotypes in humans. Thus, investigation of the role
of NPs in hypertension offers an excellent example in translational medicine. In this review article,
we will summarize the most compelling evidence regarding the molecular mechanisms underlying
the physiological and pathological impact of NPs on blood pressure regulation and on hypertension
development. We will also discuss the protective effect of NPs toward the increased susceptibility to
hypertensive target organ damage.
Keywords: natriuretic peptides; hypertension; stroke; cardiac hypertrophy; linkage analysis; genetic
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1. Introduction
Hypertension is a complex trait that results from both environmental and genetic factors [1].
Several mechanisms have been highlighted as potential contributors to the etiopathogenesis of
essential hypertension, mostly based on common knowledge of blood pressure regulation. In this
regard, the biological properties of the cardiac natriuretic peptides (NPs)—that is, natriuresis, diuresis,
and vasorelaxation [2], implying a direct modulatory role on blood pressure homeostasis—make all
components of the NP family, including the natriuretic peptide receptors (NPRA (type A natriuretic
peptide receptor), NPRB (type B natriuretic peptide receptor), and NPRC (type C natriuretic peptide
receptor)), and the related protease convertases (furin, corin, PCSK6), as major etiopathogenetic
candidates for hypertension. Moreover, the functional properties of these hormones involve
anti-hypertrophic, anti-proliferative, and anti-inflammatory effects [3] that may significantly impact
on the process of cardiovascular remodeling, such as that observed in hypertension.
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Herein, we present evidence supporting the contribution of NPs to hypertension development
obtained by both experimental and clinical investigations. As will be outlined below, the most
compelling evidence derives from the genetic approach. The impact of NPs on the pathogenesis of
hypertensive target organ damage will be also discussed.
2. Role of NP Circulating Levels in the Development of High Blood Pressure
Several physiological experiments have shown that αANP, the product of the cleavage of proANP
by corin, along with the N-terminal residues 1–98, is a key regulator of systemic blood pressure
through its natriuretic, diuretic, and vasorelaxant properties, all mediated by the type A natriuretic
peptide receptor (NPRA) [3]. As a consequence, a reduction of ANP favors high blood pressure,
whereas its increase may serve as a pharmacological tool to lower blood pressure levels. In fact,
evidence that ANP levels contribute to hypertension has been initially shown by testing the effects of
its infusion in hypertensive patients [4,5]. Subsequently, the anti-hypertensive effect of NPs has been
documented in different pathological contexts, such as primary aldosteronism [6], pheochromocytoma [7],
and hyperthyroidism [8]. In each of these conditions, the increase of NPs is able to counteract the
pro-hypertensive effect of the specific endocrine disorder. Moreover, since diuresis represents a major
action of NPs, the diuretic therapy reduces NP levels [9].
The genetic/molecular approach, undertaken over the last three decades, has the merit to provide
further support to the significant association between NP levels and hypertension. In fact, it was shown
that the knockout of Nppa (the gene encoding ANP) led to salt-sensitive hypertension in mice [10].
Consistently, the overexpression of Nppa led to hypotension [11]. Similarly, lack of NPRA caused
salt-sensitive hypertension in mice [12].
On the other hand, the biologically active carboxy-terminal peptide (BNP 1–22), derived from the
cleavage of the proBNP precursor by both furin and corin [13], appears to have a weaker impact on
the pathogenesis of hypertension compared to ANP at the experimental level. In fact, deletion of Nppb
in mice led to cardiac fibrosis rather than to hypertension development [14]. A hypertensive effect due
to lack of Nppb was documented only in a rat model [15].
The results of the genetic manipulations in rodents stimulated several studies aimed at identifying
the contribution of NPs to human hypertension. In this regard, the association of human NPPA/NPPB
gene variations with circulating ANP and BNP levels was investigated for selected single nucleotide
polymorphisms (SNPs) with the achievement of some remarkable results. Of note, we reported an
association of the –664C > G minor allele located within the NPPA promoter and associated with
lower plasma ANP levels, early onset of blood pressure increase, and the predisposition to develop
hypertension in a general population from Southern Italy [16]. Contrasting evidence was obtained for
the same SNP in a Japanese cohort of hypertensive patients [17].
Another NPPA variant, rs5063 (–664G > A), falling within the exon 1 of the gene and responsible
of a Val-to-Met transition, was associated with blood pressure progression in the Women’s Genome
Health Study and with reduced blood pressure levels in a Chinese population [18,19]. A SNP in linkage
disequilibrium with rs5063 (1837G > A, detected by a HpaII restriction fragment length polymorphism)
was associated with higher occurrence of hypertension in whites and African–American subjects [20].
Interestingly, two studies associated variants near the NPPA/NPPB locus with proANP, BNP,
and NT-proBNP levels [21,22]. Among others, the minor allele at rs5068 NPPA variant turned out
to be associated with higher ANP levels and with hypertension risk [21]. In this regard it has been
shown that this variant falling within the 3’-UTR of NPPA, affects the quantity of the ANP transcript
through an interference with the microRNA-425 [23]. In particular, in the presence of rs5068 minor
allele, the microRNA-425 cannot bind to NPPA to inhibit the gene transcription. As a consequence,
the ANP levels increase [23]. Moreover, lower blood pressure levels and reduced risk of hypertension
were observed [21,24–26].
Subsequently four genome-wide association studies (GWAS) analyzed circulating BNP or
NT-proBNP levels in association with trans loci near LOXL2, SLC39A8, KLKB1, and GALNT4 [27–30].
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As a result of the abovementioned studies, genetic variants at the MTHFR-NPPB locus (mapping
on human chromosome 1 and containing both NPPA and NPPB) appeared to act through increased
ANP/BNP production to lower blood pressure levels and, consequently, to influence susceptibility to
hypertension development. However, there was a need to more precisely identify the variants truly
associated with a change in NP levels within the MTHFR-NPPB locus and, therefore, responsible for
the hypertensive effects, which prompted subsequent investigations. In fact, a recent study testing
eight independent genetic variants in two known loci (NPPA-NPPB and POC1B-GALNT4) and one
novel locus (PPP3CC) found that only those variants correlated with midregional proANP levels had a
statistically significant, albeit weak, impact on blood pressure, whereas variants affecting BNP levels
did not [31].
Although the latter evidence appeared to further support the experimental findings in favor of
a major role of ANP, rather than BNP, on blood pressure regulation and hypertension development,
NPPB cannot be completely ruled out as a “hypertensive” gene. A single SNP, the rs198389 functional
variant in the NPPB promoter region, is associated with NT-proBNP levels in several populations [32].
In a large biracial prospective cohort study, the rs198389 NPPB promoter variant was found to be
highly associated with large differences in NT-proBNP levels in both black and white populations.
Patients with the AG and GG genotypes had progressively higher NT-proBNP levels compared to
those with AA genotype. Patients with the GG genotype had reduced systolic blood pressure and
diastolic blood pressure levels and were 15% less likely to take anti-hypertensive medications and 19%
less likely to have a diagnosis of hypertension [33].
3. Role of Other Components of the NP Family
The involvement of other members of the NP family in protection from the development of
hypertension has been mainly discovered through the genetic approach, starting with the experimental
evidence in mice and then moving to the human disease. Thus, both gene deletions in mice and
functional variants of the corresponding human genes encoding corin, furin, NPRA, and NPRC
receptors have been associated with hypertension.
Corin is the physiological proANP convertase that activates proANP in a sequence-specific
manner [34]. Blocking corin expression inhibits proANP processing in cardiomyocytes [35].
The fundamental relevance of corin for the maintenance of normal blood pressure levels was revealed
by the corin knockout mice model. This model carries undetectable levels of mature ANP and it
develops salt-sensitive hypertension with cardiac hypertrophy [36].
A recent study revealed that proprotein convertase subtilisin/kexin-6 (PCSK6), a protease
belonging to the PCSK family, is the long sought-after specific corin-activating enzyme and, as such,
is a critical regulator of the whole cascade leading to proANP processing and to αANP release
into circulation, ultimately controlling water–electrolyte and blood pressure homeostasis [37,38].
PCSK6 cleaves corin at the conserved activation site, converting zymogen corin to an active enzyme.
PCSK6 knockout mice have no detectable corin activity in the heart and develop salt-sensitive
hypertension [37], indicating a key role of PCSK6 in regulating corin activity and blood pressure
levels. Interestingly, PCSK6-mediated processing of corin is reduced in the presence of corin variants
(T555I and Q568P) previously associated to hypertension and to heart disease in black people [39,40],
as well as in the presence of corin variants (K317E, S472G, and R539C) previously identified in patients
with preeclampsia and hypertension [41]. More recently, nine corin variants were identified in a
Chinese population, of which eight were characterized for the first time. Among them, the p.Arg530Ser
and p.Thr924Met variants had reduced proANP processing activity, due to endoplasmic reticulum
retention and impaired PCSK6-mediated zymogen activation, respectively [42].
The proprotein processing enzyme furin is the mammalian prototype of the subtilisin-like serine
endoprotease family. These enzymes possess cleavage specificity for sites involving multiple basic
amino acid residues and process several precursor proteins belonging to a variety of regulatory
peptides and proteins [43]. In fact, furin is the enzyme responsible for the cleavage of proBNP and
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proCNP. It also cleaves pro-renin receptor, epithelial sodium channel, and TGF-β [43]. Based on its
functional properties, the gene encoding furin can be considered a suitable candidate for hypertension
development. However, despite its involvement in several pathways, only weak evidence in favor
of a role of furin gene in hypertension has been provided, so far, by both a GWA study and a few
case–control association studies [44,45].
The deletion of NPRA gene leads to salt-sensitive hypertension and left ventricular hypertrophy
(LVH) in mice [12]. An insertion–deletion mutation in the 5’-UTR region of the human NPRA gene
has been described [46]. The mutant allele lacks eight nucleotides and alters binding sites for the
AP2 and zeste transcriptional factors. The transcriptional activity of the deletion allele is shown to be
30% lower than that of the wild-type allele. Subjects carrying the deletion allele were significantly
more common in a Japanese population of hypertensive patients compared to the normotensive
group [46]. These findings suggested that the deletion of the NPRA reduces receptor activity in
Japanese individuals and may confer increased susceptibility to developing essential hypertension or
left ventricular hypertrophy.
More interesting findings were obtained for the NPRC gene encoding the NP clearance receptor.
In fact, in two large studies, a gene-centric array and a GWA study identified few blood pressure
loci, including one containing NPRC [44,47]. A small case-control association study, utilizing SNPs
belonging to NPRC, detected an association with hypertension and even with family history of
hypertension [48]. A recent study had the merit to confirm, first of all, using a genome-wide approach,
the existence of two independent blood pressure-related signals within NPRC. Moreover, the biological
relevance of one variant (rs1173771) was demonstrated by showing its association with lower NPRC
gene and protein expression in vascular smooth muscle cells [49].
In contrast to the significant results obtained with both NPRA and NPRC, no relevant variants
were identified in the NPRB gene in association with essential hypertension.
4. Impact of NPs on Predisposition to Develop Hypertensive Target Organ Damage
The anti-remodeling properties of NPs may certainly explain their implication in the protection
from the development of micro- and macrovascular damage, as well as of cardiac damage, that is
associated with hypertension.
One of the most dramatic results of the hypertensive vascular damage is the occurrence of
stroke [50]. The first evidence that Nppa was involved in the pathogenesis of stroke associated with
hypertension was obtained in the animal model of the stroke-prone spontaneously hypertensive rat
(SHRSP) through a genetic linkage analysis approach [51]. The latter was performed in a F2-hybrid
cohort obtained from the SHRSP/stroke resistant SHR (SHRSR) intercross, considering the latency to
stroke occurrence upon a high-salt dietary regimen as the stroke phenotype [51]. In fact, Nppa turned
out to map, together with Nppb, at the peak of linkage of a quantitative trait locus (QTL) for stroke on
rat chromosome 5 in this rat model [51]. The sequence analysis of both genes revealed the presence
of two functional variants within Nppa (but none within Nppb), one located within the promoter
region, the second one located within the coding part (exon 2). The Nppa variants were shown to
cause an altered regulation, pro-peptide processing, and peptide function [52,53], further supporting
their contribution to the development of cerebrovascular damage in SHRSP. Furthermore, the altered
regulation of Nppa expression in the brain was found to co-segregate with increased susceptibility to
stroke in the SHRSP/SHRSR F2-hybrid cohort [54].
Of note, the Nppa was excluded as a candidate gene for stroke in the SHRSP/Wistar Kyoto (WKY)
genetic linkage analysis approach [55,56]. The different genetic background and the different stroke
phenotype used in the latter study (the brain injury area produced by the middle cerebral artery
occlusion, MCAO, as opposed to the stroke latency upon high salt diet used in the previous model)
may certainly explain, at least in part, the different result. Despite the negative result of the genetic
analysis in the study by Jeffs et al. [55], more recent evidence demonstrates that cerebral overexpression
of ANP is vital to protection from brain damage in rats exposed to MCAO [57]. In fact, increased
Int. J. Mol. Sci. 2019, 20, 798 5 of 12
levels of ANP, achieved through an intraventricular injection, caused a significant reduction of the
brain injury area [57]. Consistently it is noteworthy that a pharmacological treatment of high-salt fed
SHRSP with a novel class of drugs (the type 1 angiotensin II receptor and neprilysin (NEP) inhibitor,
ARNi) led to a dramatic reduction of stroke occurrence along with a significant increase of ANP levels
in both circulation and brain tissue [58]. The latter evidence reinforces the beneficial cerebrovascular
properties of ANP.
Moreover, when translating the experimental findings to human disease, NPPA was confirmed as a
risk factor for stroke in the presence of specific variants responsible for either altered gene expression or an
altered protein function [26]. In particular, the T2238C variant, falling within exon 3 of the gene and causing
the synthesis of a peptide carrying two extra arginines, is the most common NPPA variant associated with
stroke [59,60]. The mutant peptide favors stroke through the production of an altered endothelial function,
reduced endothelium-dependent vasodilation, vascular smooth muscle cells constriction, increased
platelet aggregation through a NPRC deregulated activation [61–67]. Interestingly, subjects carrying this
variant are also at increased risk of ischemic heart disease [66]. Finally, a gene-by-treatment interaction
was observed for the T2238C NPPA variant and the use of diuretic drug (chlortalidone) in a large cohort of
hypertensive patients from the ALLHAT trial [68]. In this study, patients carrying the C variant allele had
a better response to the diuretic therapy [68], suggesting a defective diuretic action of the mutant peptide.
The anti-hypertrophic and anti-fibrotic effects of ANP underlie its involvement in the pathogenesis
of LVH in hypertension. The modulation of cardiac hypertrophy and fibrosis by ANP is achieved
through the activation of several signaling pathways, such as the calcineurin/NFATt, sodium exchanger
NHE-1, and TGFβ1/Smad pathways [69]. Thus, ANP behaves as a friend within the heart to protect it
from stress stimuli [70]. At the experimental level the knockout of Nppa leads to cardiac hypertrophy
in mice [10]. The same result is achieved when the NPRA gene is lacking [12] and also in the absence
of corin [36]. In these models, the degree of LVH is unrelated to the levels of high blood pressure.
In humans, we demonstrated that a promoter variant of NPPA causing reduced expression was
associated with LVH in a cohort of hypertensive patients independently from the blood pressure
levels [71]. Similarly, patients affected by the metabolic syndrome (that includes the diagnosis of
hypertension) have plasma ANP levels inversely related to the degree of LVH such that the lower the
ANP levels, the higher the degree of cardiac hypertrophy [72].
All components of the NP family are expressed in the kidney where they preserve renal
function [73]. As a consequence, alteration of the NP system may contribute to renal damage occurrence
in hypertension. In this regard, it has been reported that targeted disruption of NPRA provokes renal
tubular damage and interstitial fibrosis with inflammation [74]. On the other hand, chronic ANP
treatment ameliorates hypertension and end-organ damage in the kidney by reducing oxidative stress,
increasing NO system activity, and diminishing collagen content and apoptosis in the SHR animal
model [75]. Consistently, a significant protection from renal damage was also observed in the SHRSP
receiving ARNi compared to SHR receiving valsartan alone [58]. As pointed out above, only ARNi
treatment is able to increase the ANP levels.
NT-proBNP/BNP serves as a useful diagnostic and prognostic tool in heart failure, that is a
frequent complication of the hypertensive cardiac damage. Of note, this component of the NP family
has revealed a significant role into the prognosis of target organ damage in hypertensive patients [76,77].
However, in contrast to ANP, a direct involvement of BNP in the susceptibility to develop hypertensive
target organ damage has not been proven either in animal models or in humans.
NPRC plays a fundamental role in NP clearance [2]. Specifically, it recognizes an 8 aa linear fragment
of ANP molecule to perform peptide clearance. This process requires the ANP-NPRC internalization and
is followed by ANP hydrolysis by lysosomes. In addition to its well-known function in NP clearance,
NPRC can produce biological effects through the inhibition of adenylate cyclase and the involvement of
Gi inhibitory proteins. Of note, its activation mediates the deleterious effects of the abovementioned
T2238C ANP variant [62–64]. Evidence of a role of NPRC variants in the pathogenesis of hypertensive
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target organ damage, such as stroke, has been suggested by a GWA study [78]. We demonstrated that
NPRC –55C > A transition contributes to the risk of early-onset ischemic stroke in an Italian cohort [79].
5. NP-Based Therapies for the Treatment of Hypertension and Related Organ Damage
This issue will be afforded by other articles from eminent scientists in this special issue of the
Journal. As underscored by the experimental and human evidence discussed above, it is clear that
within the NP family, ANP is the most suitable and efficacious anti-hypertensive agent. However,
ANP cannot be administered orally. After many years of efforts, failures, and discoveries one later
solution has been proposed in the form of a combination of a NEP inhibitor and an angiotensin II AT1
receptor blocker. NEP is responsible for the degradation of NPs, particularly ANP, and of angiotensin
II [80]. This pharmacological combination, called ARNi, favors the protective effects of increased
ANP levels along with inhibition of the negative effects of increased angiotensin II. ARNi is currently
only indicated for the treatment of heart failure with reduced ejection fraction, but it shows potential
to become a great solution for the treatment of hypertension, as documented by a few available
experimental and human studies [58,81–86].
In summary, as represented in Figures 1 and 2, the molecular implications of the NP system, in the
pathogenesis of hypertension and related vascular damage, are of key relevance. This system offers an
excellent example in the field of translational medicine.
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Figure 1. Left side: Schematic representation of the ANP processing, receptor interaction, and physiological
functions. The ANP clearance by both NPRC and NEP is also shown. Right side: Summary of the
experimental and clinical evidence showing the pathological consequences of the ANP, NPRA, corin
gene deletions and gene mutations. ANP, atrial natriuretic peptide; ARNi, angiotensin type 1 receptor
neprilysin inhibitor; LVH, left ventricular hypertrophy; NEP, neprilysin; NPPA, ANP gene; NPRA and
NPRC, type A and type C natriuretic peptide receptors; NTpro-ANP, amino terminal pro-ANP; PCSK6,
proprotein convertase subtilisin/kexin-6.
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